<unk>  is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia. It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.
IVX-411
VIR-576
VISTA 
MPI-CDG
TA-CD
OSU-6162
STAR*D
Pro-ana